Patents by Inventor Edward C R Smith

Edward C R Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted carboxamides
    Patent number: 7960419
    Abstract: This application relates to a substituted carboxamide compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein, a pharmaceutical composition thereof, and its use in treating pain.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: June 14, 2011
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Matthew Joseph Fisher, Sean Patrick Hollinshead, Steven Lee Kuklish, Edward C R Smith, Kumiko Takeuchi
  • Tetrahydrocarbazole derivatives useful as androgen receptor modulators
    Patent number: 7935722
    Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: May 3, 2011
    Assignee: Eli Lilly and Company
    Inventors: Kevin Robert Fales, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews, David Andrew Neel, Edward C R Smith
  • Sulphonamide derivatives
    Patent number: 7135487
    Abstract: The present invention relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: November 14, 2006
    Assignee: Eli Lilly and Company
    Inventors: Macklin B Arnold, Stephen R Baker, Thomas J Bleisch, Buddy E Cantrell, Ana M Escribano, Ken Matsumoto, Tracey E McKennon, Paul L Ornstein, Richard L Simon, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M Zimmerman
  • Pyrrole derivatives as pharmaceutical agents
    Patent number: 7087626
    Abstract: Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Todd Vincent DeCollo, Alexander Glenn Godfrey, Theodore Goodson, Jr., Hong-Yu Li, William Thomas McMillen, Shawn Christopher Miller, Jason Scott Sawyer, Edward C. R. Smith, Jonathan Michael Yingling
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Spla2 inhibitors
    Patent number: 6916840
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Heterocycle substituted diphenyl leukotriene antagonists
    Publication number: 20040198779
    Abstract: The invention relates to novel heterocycle substituted diphenyl leukotriene B4 (LTB4) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.
    Type: Application
    Filed: January 28, 2004
    Publication date: October 7, 2004
    Inventors: Jason Scott Sawyer, Douglas Wade Beight, Edward C. R. Smith, William Thomas McMillen
  • Heterocycle substituted diphenyl leukotriene antagonists
    Patent number: 6797723
    Abstract: The invention relates to novel heterocycle substituted diphenyl leukotriene B4 (LTB4) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: September 28, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jason Scott Sawyer, Douglas Wade Beight, Edward C R Smith, William Thomas McMillen
  • sPLA2 inhibitors
    Patent number: 6730694
    Abstract: A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, John Michael Morin, Jr., Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040077704
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 22, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063967
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Spla2 inhibitors
    Publication number: 20040059130
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Sulphonamide derivatives
    Patent number: 6693137
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Cyclopentyl sulfonamide derivatives
    Patent number: 6639107
    Abstract: The present invention provides certain cyclopentyl sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a mammal. It also relates to novel cyclopentyl sulfonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: James Abraham Aikins, Edward C R Smith, Timothy Alan Shepherd, Dennis Michael Zimmerman
  • 2-propane-sulphonamide derivatives
    Patent number: 6596716
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain 2-propane-sulphonamide derivatives. It also relates to novel 2-propane-sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: July 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Tracey E McKennon, Paul L Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M Zimmerman
  • Sulfonamide derivatives
    Patent number: 6552086
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Patent number: 6500865
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: December 31, 2002
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Benzimidzolyl neuropeptide Y receptor antagonists
    Publication number: 20020007071
    Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.
    Type: Application
    Filed: November 30, 2000
    Publication date: January 17, 2002
    Inventors: Thomas Charles Britton, Robert Frederick Bruns, Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
  • Sulphonamide derivatives
    Patent number: 6303816
    Abstract: Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R1—L—NHSO2R2  I in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are at
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: October 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Macklin B Arnold, Stephen R Baker, David Bleakman, Thomas J Bleisch, Buddy E Cantrell, Ana M Escribano, Ken Matsumoto, Tracey E McKennon, Paul L Ornstein, Richard L Simon, Edward C. R. Smith, Joseph P Tizzano, Hamideh Zarrinmayeh, Dennis M Zimmerman